Magnesium Deficiency Treatment

Introduction to Magnesium Deficiency

Magnesium deficiency symptoms include abdominal cramps, impaired healing, fatigue, bone pain, and neurological symptoms such as confusion, irritability, and seizures, according to the European Society of Clinical Nutrition and Metabolism 1, 2
The recommended daily allowance for magnesium is 320-350 mg/day for women and 420 mg/day for men, with a Tolerable Upper Intake Level from supplements of 350 mg/day, which helps prevent adverse effects in the general population, as suggested by the Mayo Clinic Proceedings and the National Institute of Diabetes and Digestive and Kidney Diseases 3, 4

A magnesium level of 1.6 mg/dL represents severe hypomagnesemia that requires immediate treatment due to the significant risk of life-threatening cardiac arrhythmias, particularly polymorphic ventricular tachycardia (torsades de pointes) 5
Cardiac manifestations of hypomagnesemia include ventricular arrhythmias, including torsades de pointes, ECG changes (U waves, T-wave flattening), and increased sensitivity to digoxin toxicity 5
For severe hypomagnesemia with cardiac manifestations, the American Heart Association recommends IV magnesium 1-2 g of MgSO4 bolus for cardiotoxicity and cardiac arrest, particularly in polymorphic ventricular tachycardia (torsades de pointes) 5
The recommended dosage for torsades de pointes is 1-2 g IV bolus diluted in 10 mL D5W (Class IIb, LOE C) 6

If symptomatic (cardiac arrhythmias, seizures, tetany), administer IV magnesium 1-2 g of MgSO4 bolus immediately 5
Magnesium oxide at 12-24 mmol daily is the recommended first-line oral option for magnesium repletion, preferably administered at night to maximize absorption, according to the European Society of Gastrointestinal Endoscopy 7
Liquid or dissolvable magnesium products are better tolerated than pills, according to the Mayo Clinic Proceedings 3
Gradual titration of magnesium is recommended, increasing gradually according to tolerance due to potential gastrointestinal side effects, as advised by the Mayo Clinic Proceedings 3
Rehydration to correct secondary hyperaldosteronism is an important first step before magnesium repletion, as recommended by the European Society of Gastrointestinal Endoscopy 7
Correct hypomagnesemia before addressing hypokalemia, as potassium replacement may be ineffective until magnesium is repleted in patients with electrolyte imbalances 7
The following treatment guidelines are recommended:

Condition	Recommended Treatment
Life-threatening arrhythmias	IV magnesium and potassium
Less critical situations	Oral supplementation
Cardiac arrest with known or suspected hypermagnesemia	IV calcium instead of magnesium
Magnesium deficiency	Magnesium replacement
Hypermagnesemia	Avoid magnesium co-administration

For severely malnourished patients, magnesium requirements are approximately 0.4 mmol/kg/day orally (or 0.2 mmol/kg/day if supplied intravenously), as suggested by Clinical Nutrition 12, 13
The following monitoring schedule is recommended:

Population	Monitoring Schedule
Children	Weekly for the first 2 months, monthly for months 2-6, and every 3-6 months for young children and every 6-12 months for older children after 6 months
Children with renal dysfunction	Every 1-2 weeks
Children on calcineurin inhibitors	More frequent monitoring due to the increased risk of hypomagnesemia

Serum magnesium levels, along with associated electrolytes such as calcium, phosphorus, and potassium, should be monitored in patients with renal insufficiency or kidney disease, as recommended by the American Society of Nephrology 14, 15

Avoid magnesium in patients with severe renal impairment (creatinine clearance <20 mg/dL), as advised by the American Gastroenterological Association 17
Monitor for diarrhea which can worsen with magnesium supplementation, as recommended by the European Society of Gastrointestinal Endoscopy 1
Medications such as diuretics, proton pump inhibitors, certain antibiotics, and chemotherapeutic agents (cisplatin, cetuximab) are common causes of hypomagnesemia, particularly in elderly patients with heart failure, and polypharmacy (≥5 medications) significantly increases the risk of hypomagnesemia 2, 18
The European Society of Cardiology recommends avoiding potassium-sparing diuretics during the initiation of ACE inhibitor treatment to prevent hyperkalemia in patients with cardiovascular disease 19
The European Society of Cardiology recommends considering reducing diuretic dose or adding potassium-sparing diuretic if diuretic-induced hypokalemia is present, to prevent further electrolyte imbalances in patients with cardiovascular disease 19, 20